Radiation therapy plays a vital role in cancer treatment. However, its effects on normal tissues are a significant concern. The intestinal epithelium, which serves as a frontline barrier against pathogens and is crucial for nutrient absorption, often suffers severe damage due to radiation. This damage manifests as inflammation, edema, and, in severe cases, necrosis. Such reactions can lead to dire complications, including debilitating gastrointestinal symptoms and detrimental impacts on patient quality of life. As a result, protecting the intestinal lining during radiation therapy emerges as a crucial objective in oncological care.

The authors of the study turned their attention toward gasdermin E, a protein involved in pyroptosis – a form of programmed cell death that is distinct from apoptosis. Pyroptosis is characterized by the formation of pores in the cellular membrane, leading to cell lysis and the release of inflammatory cytokines. This process is beneficial in some contexts, such as infectious diseases, but becomes detrimental in the setting of tissue damage, like that induced by radiation. By targeting pyroptosis, particularly gasdermin E-mediated pathways, the team sought to identify a therapeutic strategy that could minimize collateral damage while preserving the integrity of intestinal cells.

Nicotinamide riboside has gained attention for its role as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme critical for various metabolic processes and cellular repair mechanisms. By augmenting NAD+ levels, NR has been shown to enhance mitochondrial function and promote cellular resilience against stressors. These properties position NR as a promising candidate for reducing tissue damage in scenarios where cells are subjected to inflammatory and oxidative stresses.

The research led by Zhou and colleagues meticulously demonstrated that treatment with NR significantly reduced markers of intestinal injury in preclinical models exposed to ionizing radiation. The investigators employed various in vitro and in vivo models to carefully evaluate the biochemical pathways activated by NR. They found that NR application resulted in lowered activation of gasdermin E, implying that the compound effectively curbed pyroptosis within intestinal epithelial cells. This elegant mechanism underscores the unique ability of NR to navigate cellular responses to radiation exposure.

One of the most compelling aspects of this study was the observed reduction in pro-inflammatory cytokines following NR treatment. Cytokines are messengers in the immune system, and their excess production can aggravate tissue damage and prolong inflammation, creating a vicious cycle of cellular injury. By mitigating the release of these cytokines, NR does not just protect intestinal cells but also potentially alleviates the overarching inflammatory response, thus paving the way for improved recovery.

Interestingly, the results indicated that NR administration led to enhanced intestinal barrier function. This critical outcome has vast implications for patient management in clinical settings. A robust intestinal barrier prevents the translocation of bacteria and toxins from the gut into systemic circulation, which can provoke septic complications in vulnerable patients. By reinforcing this barrier, NR may hold the key to reducing both local and systemic complications associated with radiation therapy.

The potential applications of NR extend beyond radiation therapy. Considering its mode of action, the findings may provide insights into developing therapies for other conditions associated with intestinal injury, including inflammatory bowel diseases and even acute pancreatitis. The versatility of NR as a protective agent suggests it could play a role in a broader therapeutic context, thereby appealing to a wide range of patients suffering from gastrointestinal distress.

As the medical community continues to explore NR’s therapeutic window, further studies will be vital in optimizing dosages and administration routes. Understanding the pharmacokinetics of NR and potential interactions with existing treatments will be crucial to its successful integration into clinical practice. Early-phase trials could rapidly follow, as there is a strong impetus for finding interventions to improve outcomes during chemotherapy and radiation therapies.

In conclusion, the research conducted by Zhou and his team provides a promising avenue for the use of nicotinamide riboside as a protective agent against radiation-induced intestinal injury. Through its elegant action on gasdermin E-mediated pyroptosis, NR opens doors to enhanced patient care in oncology. The drive towards translational research in this domain offers a glimmer of hope for patients undergoing radiation therapy, hinting at improved quality of life and therapeutic outcomes in the future.

As we await further investigations into the clinical feasibility of NR, the scientific community can celebrate a vital step towards innovative strategies in cancer treatment, where protection of the intestinal barrier could lead to a paradigm shift in patient care. The disruptions caused by radiation therapy may soon be alleviated by the harnessing of natural compounds such as nicotinamide riboside, providing renewed optimism for both patients and physicians alike.

Ultimately, the advances in our understanding of cellular responses to radiation injury and the potential for targeted interventions highlight a critical era in medical science where nutrition and molecular biology intersect to yield unexpected treatments. These insights underscore the importance of continued investment in research that aims to unlock the healing promises of the molecules within our reach.

Subject of Research: Radiation-induced intestinal injury and protective agents

Article Title: Nicotinamide riboside attenuates radiation-induced intestinal injury by suppressing gasdermin E-mediated pyroptosis in intestinal epithelial cells

Article References:

Zhou, Q., Liu, L., Lin, X. et al. Nicotinamide riboside attenuates radiation-induced intestinal injury by suppressing gasdermin E-mediated pyroptosis in intestinal epithelial cells. J Transl Med 23, 1126 (2025). https://doi.org/10.1186/s12967-025-07012-1

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07012-1

Keywords: Nicotinamide riboside, radiation therapy, intestinal injury, gasdermin E, pyroptosis, cytokines, intestinal barrier.

Prostate cancer recurrence poses a formidable challenge in oncological care, often eluding detection by standard imaging modalities such as bone scans and computed tomography (CT). The innovative PSMA PET scan involves the intravenous administration of a radiolabeled molecule engineered to selectively bind PSMA, a cell surface protein abundantly expressed on prostate cancer cells. This molecular targeting ensures high-contrast images by highlighting metastatic deposits with exceptional specificity and sensitivity. The study conclusively demonstrates that PSMA PET scanning identifies sites of cancer recurrence with a detection rate of approximately 70 percent, substantially surpassing historical detection rates ranging between 10 and 20 percent achieved by traditional imaging.

Dr. Glenn Bauman, a leading Radiation Oncologist at London Health Sciences Centre and Scientist at LHSCRI, emphasizes the clinical implications of this advancement: “The superior precision of PSMA PET scans allows us to detect recurrent cancer at an earlier stage and to pinpoint its exact anatomical location. This empowers clinicians to tailor therapeutic interventions specifically to the affected sites rather than resorting to systemic therapies that can be less targeted and more toxic.” This refined diagnostic capability not only enhances treatment accuracy but also enables a paradigm shift towards personalized oncology.

An essential finding from the multicenter study is the dramatic impact of PSMA PET findings on therapeutic decision-making. Approximately 50 percent of patients experienced modifications in their clinical management following PSMA PET imaging. More strikingly, nearly 90 percent of men with lesions detected via PSMA PET underwent changes in their treatment regimens, underscoring the scan’s influence on clinical practice. These treatment adaptations ranged from localized radiotherapy targeting discrete metastatic foci to the strategic initiation or alteration of systemic therapies based on precise disease burden assessments.

Beyond detection, the study highlights an observed survival advantage among patients whose management was guided by PSMA PET imaging compared to those evaluated using conventional methods. This suggests that the earlier and more accurate identification of recurrence facilitated by PSMA PET directly contributes to improved long-term outcomes, likely through enabling timely and appropriately targeted interventions. According to Dr. Ur Metser, Division Head of Molecular Imaging at UHN and Clinician Scientist at Princess Margaret Cancer Centre, “Our findings represent a monumental shift towards precision medicine in the management of recurrent prostate cancer, translating into tangible survival benefits.”

The scientific rigor of this research is further reflected in its extensive scope, enrolling thousands of men from six different hospitals across Ontario. Initiated in 2016 with the first use of PSMA PET imaging in Canada by Dr. Bauman and colleagues, the study has garnered robust funding support through Ontario Health – Cancer Care Ontario. This has facilitated comprehensive data collection, validation, and multi-institutional collaboration essential for establishing PSMA PET as a new standard of care.

Technically, PSMA PET imaging leverages positron emission tomography’s capability to detect gamma rays emitted indirectly by the radiotracer administered to patients. The tracer binds to PSMA-expressing prostate cancer cells with high affinity, accumulating in both primary and metastatic tumor sites. This accumulation generates high-resolution three-dimensional images, allowing physicians to visualize cancer spread with unparalleled clarity. Such precision imaging reduces uncertainties inherent in conventional scans and significantly improves staging accuracy.

Clinically, the advent of PSMA PET imaging addresses a critical unmet need: the detection of biochemically recurrent prostate cancer when routine scans fail to localize disease despite rising prostate-specific antigen (PSA) levels. By identifying occult metastases early, PSMA PET permits focused salvage therapies, potentially delaying or obviating the need for systemic treatments that carry higher morbidity. This diagnostic innovation thus enhances patient quality of life alongside clinical outcomes.

Moreover, the implementation of PSMA PET scanning exemplifies the interplay between molecular biology and medical imaging technologies, showcasing how targeted radiotracers can revolutionize oncological imaging. The translation of discoveries from preclinical molecular studies into clinical applications epitomizes modern precision oncology. As PSMA-targeted agents continue to be refined, future developments may include theranostic approaches that combine diagnostic imaging with targeted radionuclide therapy.

The broad adoption of PSMA PET scans as a funded healthcare service in Ontario marks a noteworthy policy achievement. It demonstrates confidence in this technology’s clinical utility and cost-effectiveness to justify public health investment. This could serve as a model for other regions seeking to integrate advanced molecular imaging into prostate cancer care pathways, promoting equitable access to cutting-edge diagnostics.

In summary, the transformative impact of PSMA PET scanning in the early detection and precise localization of prostate cancer recurrence represents a major leap forward in cancer imaging. This diagnostic tool enables oncologists to make informed, targeted treatment decisions that improve survival rates and personalize patient care. As research and clinical experience accumulate, PSMA PET promises to redefine standards of care for men battling recurrent prostate cancer, offering renewed hope and improved prognoses.

Subject of Research: People
Article Title: Not specified
News Publication Date: Not specified
Web References: The Journal of Nuclear Medicine article
Image Credits: LHSC
Keywords: Clinical medicine, Health and medicine

FaceAge employs sophisticated deep learning algorithms, a subset of artificial intelligence that excels at recognizing complex patterns within images, to analyze subtle features within a patient’s face. The model was trained on an extensive dataset comprising nearly 59,000 photographs of presumed healthy individuals, sourced from publicly available datasets, to learn normative aging patterns. This foundational training makes the model sensitive to variances beyond chronological time, identifying aging markers that may signal underlying physiological or pathological changes invisible to the naked eye.

Following initial training, FaceAge was rigorously tested on a cohort of over 6,000 cancer patients from two distinct medical centers, utilizing photographs routinely taken at the outset of radiotherapy treatment. The results revealed a striking trend: cancer patients consistently exhibited a biological age—an inferred FaceAge—that was roughly five years older than their actual chronological age. This disparity suggests that their physical appearance encodes the toll that cancer and perhaps its treatments impose on the body’s biological systems.

Importantly, the researchers discovered that an elevated FaceAge correlated strongly with worse overall survival outcomes across multiple cancer types. The predictive power of FaceAge remained robust even after adjusting for traditional prognostic factors including chronological age, sex, and cancer classification, underscoring its value as an independent biomarker. Notably, patients with FaceAge estimates indicating they appeared older than 85 years faced particularly poor prognoses, making FaceAge a potentially critical tool in patient stratification and personalized treatment planning.

Predicting survival time, particularly in terminal conditions, remains a profound challenge in clinical oncology due to the complex interplay of patient variables. The Mass General Brigham team engaged ten clinicians and researchers to retrospectively evaluate short-term life expectancy from 100 patient photos undergoing palliative radiotherapy. Despite their expertise and access to clinical data, clinician predictions were only marginally better than chance. However, when clinicians were augmented with FaceAge metrics, their prognostic accuracy improved significantly, demonstrating how AI-derived biological age could complement clinical intuition and reduce subjectivity inherent in traditional assessments.

The implications of FaceAge extend beyond a single disease or even oncology itself. Facial morphology and appearance can serve as visible readouts of an individual’s complex biological aging process, which is influenced by myriad factors including genetics, environment, and disease burden. The ability to decode this information through a simple photograph opens avenues for biomarker discovery that leverage noninvasive, ubiquitous data sources. This approach holds promise not only for predicting cancer outcomes but also for early detection of chronic illnesses and monitoring general health trajectories over time.

While FaceAge’s performance is compelling, the researchers emphasize that further validation across diverse populations, healthcare settings, and disease stages is essential before clinical deployment. Ongoing studies aim to evaluate the system’s robustness in different demographic and geographic contexts, track longitudinal changes in FaceAge during disease progression or recovery, and compare its reliability against confounders such as cosmetic interventions like plastic surgery or makeup.

Technical innovation also includes the integration of FaceAge into clinical workflows in a manner that respects ethical considerations and patient privacy. The research team advocates for incorporating regulatory frameworks and transparency about algorithm limitations, to ensure that this emerging technology serves as a tool to support, rather than replace, physician judgment. Ultimately, FaceAge could revolutionize how clinicians assess biological aging and tailor individualized care pathways, making treatment more precise by integrating objective physiological metrics derived from facial imaging.

Co-senior and corresponding author Hugo Aerts, PhD, highlights the unique power of this approach: “A simple selfie contains layers of biological information that have been traditionally overlooked. This method transforms everyday data into crucial clinical insights that could refine prognostication and patient management.” Meanwhile, co-senior author Ray Mak, MD, envisions that FaceAge and similar tools could become cornerstones for early disease detection across aging-related conditions, provided their development proceeds with rigorous scientific standards and ethical oversight.

The potential applications of FaceAge also intersect with population health, as aging faces are a universal human attribute. By capturing and quantifying aging trajectories at the individual level, this technology could contribute to a broader understanding of how chronic diseases accelerate biological aging, potentially guiding public health interventions and resource allocation. Moving forward, FaceAge’s developers seek to integrate multi-modal data sources, incorporating genomic, metabolic, and lifestyle information alongside facial imaging to create comprehensive, personalized health profiles.

This research underscores a transformative moment in medicine, where artificial intelligence translates visual data into meaningful biological markers. The capacity to decode aging and prognosis from facial photographs may redefine patient evaluation, prognostication, and care personalization. As digital health technologies continue to evolve, FaceAge exemplifies the power of combining computational modeling with clinical insight, paving the way for more sophisticated, accessible, and objective health assessments in the near future.

Subject of Research: People

Article Title: FaceAge, a deep learning system to estimate biological age from face photographs to improve prognostication: a model development and validation study

News Publication Date: 8-May-2025

Web References:

• Mass General Brigham
• The Lancet Digital Health Article
• DOI Link

References:
Bontempi, et al. “Decoding biological age from face photographs using deep learning.” The Lancet Digital Health, DOI: 10.1016/j.landig.2025.03.002

Image Credits: Mass General Brigham

Keywords: Artificial intelligence, Life expectancy, Cancer, Aging populations